Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Immunovaccine breaking ground, says Mackie, as it rates stock 'speculative buy'

Mackie reckons the firm is 'breaking ground' and targets C$2.80 for the shares..
Immunovaccine breaking ground, says Mackie, as it rates stock 'speculative buy'
The firm is operating in the field of immunology..

Broker Mackie repeated a 'speculative buy' stance on Immunovaccine Inc (TSE:IMV) following news that it was advancing its cancer vaccine into a Phase I trial.

The biotech announced an expansion of its ongoing collaboration with UConn Health  - part of Immunovaccine’s DPX-NEO program.

This is assessing the anti-cancer activity of patient specific epitopes (the part of molecule which is the target of an immune response) developed at UConn Health and formulated in Immunovaccine's proprietary delivery system.

“The potential of neoepitope-based therapies to trigger anti-cancer immune responses tailored to the unique biology of each patient’s disease could be an oncology treatment game-changer,” said Frederic Ors, Immunovaccine’s chief executive today.

Mackie agrees the firm is 'breaking ground'  and targets C$2.80 for the shares, against a current price of C$2.13 - up over 11% on the day.

DPX-NEO should diversify the group's pipeline once it enters a Phase I study, says analyst Andre Uddin, who adds there are multiple catalysts ahead for the group.

"IMV has been up 181% YTD and our call has generated a 208% return since we launched coverage," he notes.

View full IMV profile View Profile

ImmunoVaccine Timeline

Related Articles

woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch
scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use